Memantine Hydrochloride Tablet
Product Images NDC 70518-3338

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 70518-3338). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 01)

Chemical structure diagram of Memantine Hydrochloride showing the bicyclic amine framework with attached methyl groups and hydrochloride component.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 02)

A line graph depicting mean change from baseline in ADCS-ADL score over 28 weeks of treatment comparing Memantine Hydrochloride (M.HCl) and placebo groups. The vertical axis shows mean ± SEM change, with lines indicating clinical improvement and decline. Memantine Hydrochloride results in less decline over time versus placebo.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 03)

A cumulative percentage of patients line graph comparing Memantine Hydrochloride (M.HCl) to placebo based on ADCS-ADL change from baseline. The x-axis represents the ADCS-ADL change from baseline values, and the y-axis shows the cumulative percentage of patients. Two curves display the progression for placebo and Memantine Hydrochloride over the change range.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 04)

Line chart showing mean (± SEM) change from baseline in SIB score over 28 weeks of treatment. Two data series are displayed: Placebo (solid squares) showing a decline, and Memantine Hydrochloride (M.HCl, open circles) showing a smaller change. The y-axis ranges from clinical improvement to clinical decline, while the x-axis denotes weeks of treatment.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 05)

A cumulative percentage of patients versus SIB (Severe Impairment Battery) change from baseline graph comparing Memantine Hydrochloride (M. HCl) to placebo. The graph shows higher cumulative improvement in SIB scores for Memantine Hydrochloride patients compared to placebo over a range of negative SIB change values.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 06)

Line graph showing mean changes from baseline in ADCS-ADL scores over 24 weeks of treatment, comparing Placebo/Donepezil and Memantine Hydrochloride (M.HCl)/Donepezil groups. The x-axis represents weeks of treatment, and the y-axis represents mean ± SEM change scores, with markers for clinical improvement and decline.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 07)

A line graph displaying the cumulative percentage of patients against ADCS-ADL change from baseline. It compares two groups: Placebo/Donepezil and Memantine Hydrochloride (M. HCl)/Donepezil. The x-axis represents the ADCS-ADL change from baseline, and the y-axis shows the cumulative percentage of patients, indicating a shift in patient response over a range of values.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 08)

A line graph comparing the mean change from baseline in SIB score over 24 weeks of treatment between Placebo/Donepezil and Memantine Hydrochloride/Donepezil groups. The y-axis shows mean change with error bars, ranging from -4 to 4, indicating clinical decline and improvement. The x-axis represents weeks of treatment from 0 to 24. Placebo/Donepezil is marked with squares showing minimal change, while Memantine Hydrochloride/Donepezil is marked with circles showing improvement around week 12, then a gradual decline yet above baseline.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 09)

A cumulative percentage curve graph showing the distribution of patients by SIB change from baseline for two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The x-axis represents SIB change from baseline, ranging approximately from +20 to -30, and the y-axis shows the cumulative percentage of patients from 0% to 100%. The Memantine Hydrochloride/Donepezil group is represented by circles, and the Placebo/Donepezil group by squares.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Memantine Hydrochloride 5 mg oral tablets, quantity 30. Manufactured by Viona Pharmaceuticals Inc, Cranford, NJ, and repackaged by RemedyRepack Inc, Indiana, PA. Includes NDC number 70518-3338-00, storage instructions, and a readable QR code.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.